ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

Performance

52-Week Range 35.2% below 52-week high

20.07

19.5952W Low 30.9652W High

1 Week 9.6% below 1-week high

19.591W Low 22.211W High

ACADIA Pharmaceuticals Inc. - Common Stock (ACAD) traded between $19.59 and $30.96 over the past 52 weeks and last traded at $20.07, 35.2% below its 52-week high. Over the past week it ranged between $19.59 and $22.21.

Past 12 Months

-2.9%

-30.5%

-22.7%

-9.6%

-23.7%

-5.5%

1W -$0.61

1M -$8.82

3M -$5.90

6M -$2.13

YTD -$6.22

1Y -$1.17

ACAD was -5.5% over the past year, -9.6% over six months, -23.7% year to date, -2.9% in the last week.

12 Months vs Market

ACAD

-5.5%

DIA

+10.0%

SPY

+15.1%

QQQ

+24.2%

IWM

+16.1%

Over the past 12 months ACAD returned -5.5% versus DIA (Dow) +10.0%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.2% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 0.95× 3-mo avg

Today 1,704,482 3-mo avg 1.8M

3.1M

2.2M

1.8M

1.7M

YTD

1.7M

ACAD most recently traded 1,704,482 shares against a 3-month average daily volume of 1.8M.

More News

ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial ↗

September 24, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

September 24, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup ↗

August 31, 2026

Via Chartmill

ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗

August 04, 2026

Via Chartmill

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

August 24, 2026

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data ↗

August 12, 2026

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗

May 06, 2026

Via Chartmill

ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 04, 2026

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 30, 2026

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

July 20, 2026

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

July 15, 2026

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗

July 11, 2026

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

July 06, 2026

Why Acadia Pharmaceuticals Stock Is Soaring Today ↗

June 26, 2026

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday ↗

Traders are paying attention to the gapping stocks in Friday's session. ↗

June 26, 2026

Via Chartmill

June 26, 2026

Via Benzinga

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

June 26, 2026

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗

May 19, 2026

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗

May 12, 2026

Acadia (ACAD) Q1 2026 Earnings Transcript ↗

May 06, 2026

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

May 06, 2026